About Storm therapeutics limited
Storm Therapeutics Limited: Pioneering RNA Epigenetics for Cancer Treatment
Storm Therapeutics Limited is a biotechnology company based in Cambridge, UK, that specializes in the field of RNA epigenetics. The company is dedicated to developing small molecule inhibitors of RNA-modifying enzymes for the treatment of cancer. Storm Therapeutics is at the forefront of research into this exciting new area of cancer therapy and has already made significant progress towards developing effective treatments.
RNA epigenetics refers to modifications made to RNA molecules that can affect gene expression and protein production. These modifications are carried out by enzymes known as writers, erasers, and readers. Storm Therapeutics' focus is on developing small molecule inhibitors that can target these enzymes and prevent them from modifying RNA molecules in ways that contribute to cancer growth.
The company was founded in 2015 by leading experts in the field of RNA biology and epigenetics. Its founders include Tony Kouzarides, a professor at the University of Cambridge who has made significant contributions to our understanding of how gene expression is regulated through epigenetic mechanisms; Eric Miska, also a professor at Cambridge who has studied how small RNAs regulate gene expression; and Alan Lamont, an experienced biotech entrepreneur.
Since its founding, Storm Therapeutics has attracted significant investment from leading venture capital firms such as Seroba Life Sciences and Taiho Ventures LLC. The company's investors recognize the potential for its innovative approach to cancer therapy and have provided funding to support its research efforts.
Storm Therapeutics' team includes scientists with expertise in molecular biology, biochemistry, pharmacology, medicinal chemistry, and drug discovery. Together they are working towards identifying novel targets for small molecule inhibitors that can be developed into effective therapies for various types of cancer.
One promising area of research for Storm Therapeutics involves targeting an enzyme called METTL3 which plays a key role in regulating mRNA stability through m6A modification. This modification affects the stability and translation of mRNA, which in turn can affect the expression of genes involved in cancer growth. Storm Therapeutics has developed a potent and selective inhibitor of METTL3 that has shown promising results in preclinical studies.
Another area of research for Storm Therapeutics involves targeting an enzyme called ADAR1 which is involved in editing RNA molecules. This enzyme is overexpressed in many types of cancer and contributes to tumor growth by promoting the expression of oncogenes. Storm Therapeutics has developed a series of inhibitors that can selectively target ADAR1 and prevent it from promoting cancer growth.
Storm Therapeutics' innovative approach to cancer therapy has attracted attention from leading academic institutions, pharmaceutical companies, and investors around the world. The company's partnerships with these organizations have helped to accelerate its research efforts and bring its therapies closer to clinical trials.
In conclusion, Storm Therapeutics Limited is a pioneering biotechnology company focused on developing small molecule inhibitors for RNA-modifying enzymes as a novel approach to treating cancer. Its team includes leading experts in RNA biology and epigenetics who are working towards identifying novel targets for small molecule inhibitors that can be developed into effective therapies for various types of cancer. With significant investment from leading venture capital firms, promising preclinical data, and partnerships with academic institutions and pharmaceutical companies worldwide, Storm Therapeutics is well-positioned to make significant contributions towards improving outcomes for patients with cancer.
stormtherapeutics.com
